UNSPSC 51431704: Diltiazem

This classification denotes a calcium channel blocker with the molecular formula C22H26N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EE92BBP03H, chemically known as 3-acetoxy-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5h)-one but generally known as diltiazem, which bears US NIH Compound Identifier 3076. European Medicines Agency schedules Diltiazem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07148MIG.

UNSPSC 51431704 Diltiazem, a Commodity code, designates a specific cardiac medication (calcium channel blocker) that state and local governments procure as part of emergency medical services, public health, and institutional pharmacy supply chains. Diltiazem appears in recent solicitations as a line item within broader advanced life support medication contracts, hospital formulary purchases, and multi-state cooperative pharmaceutical procurement agreements. State and local issuing bodies acquiring under this code include municipal fire-rescue departments, state health and human services agencies, and multi-state cooperative purchasing alliances representing dozens of participating jurisdictions. The work itself consists of supplying finished-dose diltiazem vials or injections to emergency responders and institutional healthcare settings, with vendors responsible for meeting expiration-date warranties, OSHA safety documentation, and delivery timelines measured in days to weeks.

Recent activity clusters in Florida and the Upper Midwest. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026 (due April 8, 2026) for Advanced Life Support Medications including 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term plus two optional one-year renewals; the solicitation sheltered the award for Small Local Business Enterprises at a 5 percent discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs before issuing a formal RFP. These opportunities signal active municipal and state procurement of diltiazem as a commodity input to emergency medical and pharmacy supply contracts.